Nontoxic effect of tacrolimus on normally perfused isolated liver and protective effect on hypoperfused liver

Medical Science Monitor

Volumn 13, Issue 2, 2007, Pages

  Nakache, Richard ^a   Isretil, Ivgeny ^a   Ekstein, Perla ^a   Almogy, Nehama ^a   Fedorov, Dimitri ^a   Lifschitz Mercer, Beatriz ^a   Weinbroum, Avi A ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Calcineurin inhibitors; Hepatic low flow; Reperfusion; Tacrolimus

Indexed keywords

MICROSPHERE; SODIUM CHLORIDE; TACROLIMUS;

ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPATIC ARTERY; ISOLATED LIVER; LIVER CIRCULATION; LIVER METABOLISM; LIVER PERFUSION; LIVER PROTECTION; MALE; MICROCIRCULATION; NONHUMAN; ORGAN TRANSPLANTATION; PERFUSION; RAT; REPERFUSION; VASCULAR PATENCY;

ANIMALS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; MALE; PERFUSION; RATS; RATS, WISTAR; REPERFUSION INJURY; TACROLIMUS;

EID: 33846939831     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hadad SJ, Souza ER, Ferreira AT et al: FK 506: effects on glomerular hemodynamics and on mesangial cells in culture. Kidney Int, 1995; 48: 56
2. Mitamura T, Yamada A, Ishida H et al: Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci, 1994; 19: 219
3. Randhawa PS, Tsamandas AC, Magnone M et al: Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol, 1996; 20: 306
4. Roman ID, Monte MJ, Gonzalez-Buitrago JM et al: Inhibition of hepatocytary vesicular transport by cyclosporine A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology, 1990; 12: 83
5. Magari K, Miyata S, Nishigaki F et al: Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res, 2004; 53: 544
6. Busuttil RW, Klintmalm GB, Lake JR et al: General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation, 1996; 61: 845
7. Keenan RJ, Konishi H, Kawai A et al: Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg, 1995; 60: 580
8. Shapiro R: Tacrolimus in renal transplantation-a review. Graft, 2000; 3: 64
9. Taylor DO, Barr ML, Radovancevic B et al: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant, 1999; 18: 336
10. Nakache R, Rudick V, Fiodorov D et al: Cumulative damaging effect of liver hypoperfusion and cyclosporine A on the peribiliary capillary plexus: a study in an isolated dually perfused rat model. Transplantation, 1999; 68: 1651
11. Weinbroum AA, Kluger Y, Shapira I, Rudick V: Methylene blue abolishes aortal tone impairment induced by liver ischemia-reperfusion in a dose response manner: an isolated-perfused double-organ rat model study. Shock, 2001; 15: 226
12. Hashimoto S: A new spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal Biochem, 1974; 62: 426
13. Tan S, Yokoyama Y, Wang Z et al: Hypoxia-reoxygenation is as damaging as ischemia-reperfusion in the rat liver. Crit Care Med, 1998; 26: 1089
14. Weinbroum AA, Shapira I, Ben-Abraham R, Szold A: Mannitol dose-dependently attenuates lung reperfusion injury following liver ischemia reperfusion: a dose-response study in an isolated perfused double-organ model. Lung, 2002; 180: 327
15. Alexander B, Mathie RT, Ralevic V, Burnstock G: An isolated dual-perfused rabbit liver preparation for the study of hepatic blood flow regulation. J Pharmacol Toxicol Methods, 1992; 27: 17
16. Wingard JR, Nash RA, Przepiorka D et al: Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant, 1998; 4: 157
17. Viebahn R, de Groot H, Lauchart W, Becker HD: Hypoxic and reoxygenation injury in human and rat hepatocytes-influence of FK 506 and cyclosporine. Transplant Proc, 1991; 23: 3183
18. Fisher A, Mor E, Hytiroglou P et al: FK506 hepatotoxicity in liver allograft recipients. Transplantation, 1995; 59: 1631
19. Hytiroglou P, Lee R, Sharma K et al: FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. Transplantation, 1993; 56: 1389
20. Tsamandas AC, Jain AB, Felekouras ES et al: Central venulitis in the allograft liver: a clinicopathologic study. Transplantation, 1997; 64: 252
21. Kaibori M, Sakitani K, Oda M et al: Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-kappaB activation in rat hepatocytes. J Hepatol, 1999; 30: 1138
22. Ekataksin W, Kaneda K: Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis, 1999; 19: 359
23. Kim YI, Akizuki S, Kawano K et al: FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. Transplant Proc, 1994; 26: 2384
24. Wakabayashi H, Karasawa Y, Tanaka S et al: The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. Surg Today, 1994; 24: 994
25. St. Peter SD, Post DJ, Rodriguez-Davalos MI et al: Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl, 2003; 9: 144